CN116687850A - 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 - Google Patents
包含环状膦酸酯化合物的药物组合物及其制备方法与用途 Download PDFInfo
- Publication number
- CN116687850A CN116687850A CN202210172544.0A CN202210172544A CN116687850A CN 116687850 A CN116687850 A CN 116687850A CN 202210172544 A CN202210172544 A CN 202210172544A CN 116687850 A CN116687850 A CN 116687850A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- phosphonate compound
- cyclic phosphonate
- polyvinyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cyclic phosphonate compound Chemical class 0.000 title claims abstract description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 22
- 229920002554 vinyl polymer Polymers 0.000 claims abstract description 19
- 150000003951 lactams Chemical class 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 7
- 229920002678 cellulose Chemical class 0.000 claims abstract description 5
- 239000001913 cellulose Chemical class 0.000 claims abstract description 5
- 229920005862 polyol Polymers 0.000 claims abstract description 5
- 150000003077 polyols Chemical class 0.000 claims abstract description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 238000009474 hot melt extrusion Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000578 graft copolymer Polymers 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 3
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 3
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 208000019423 liver disease Diseases 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000005495 thyroid hormone Substances 0.000 claims description 3
- 229940036555 thyroid hormone Drugs 0.000 claims description 3
- SQNWFKZOFAOCHM-UHFFFAOYSA-N 3-azaniumyl-2-methylprop-2-enoate Chemical compound [NH3+]C=C(C)C([O-])=O SQNWFKZOFAOCHM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920001531 copovidone Polymers 0.000 claims description 2
- 238000002425 crystallisation Methods 0.000 claims description 2
- 230000008025 crystallization Effects 0.000 claims description 2
- 238000005520 cutting process Methods 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229940069328 povidone Drugs 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000000935 solvent evaporation Methods 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 33
- 238000004090 dissolution Methods 0.000 abstract description 21
- 230000008569 process Effects 0.000 abstract description 8
- 238000009776 industrial production Methods 0.000 abstract description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229920005989 resin Polymers 0.000 abstract 1
- 239000011347 resin Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 15
- 239000002775 capsule Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 239000002245 particle Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 238000001125 extrusion Methods 0.000 description 8
- 239000000693 micelle Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- GFAZGHREJPXDMH-UHFFFAOYSA-N 1,3-dipalmitoylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCC GFAZGHREJPXDMH-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 description 1
- BKVAAWMQOQLENB-UHFFFAOYSA-N 15-hydroxy stearic acid Chemical compound CCCC(O)CCCCCCCCCCCCCC(O)=O BKVAAWMQOQLENB-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229940123876 Thyroid hormone receptor beta agonist Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
- JEJLGIQLPYYGEE-UHFFFAOYSA-N glycerol dipalmitate Natural products CCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCC JEJLGIQLPYYGEE-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 229940044476 poloxamer 407 Drugs 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229940051841 polyoxyethylene ether Drugs 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种药物组合物,按重量份计,其包含1份如式(I)所示的环状膦酸酯化合物和9至45份药学上可接受的载体;一种或者多种选自聚乙烯内酰胺、纤维素衍生物、聚丙烯酸树脂、聚多元醇、聚乙烯醇或聚氧乙烯的聚合物材料。所述药物组合物能够实现环状膦酸酯化合物在溶出过程中更长时间维持过饱和浓度,而且由该组合物获得的制剂能够满足制备过程中有关物质未见显著性增加,符合工业化生产的需要,并且其最终制剂产品适合在室温(小于30℃)下贮存。本发明还提供了上述组合物的制备方法及其用途。
Description
技术领域
本发明属于药物制剂领域。具体地,本发明涉及一种包含环状膦酸酯化合物的药物组合物、其制备方法及用途。
背景技术
式(I)所示的环状膦酸酯化合物(分子式为C28H32ClO5P,分子量为514.98,CAS登记号为852948-13-1)是一种有望用于脂肪性肝脏疾病的新型口服甲状腺激素β受体激动剂(THR-beta agonist)。
中国专利申请号202010105909.9中提供了一种式(I)所示化合物的增溶组合物及其制备方法,以该方法制备的半固体胶囊需在低于室温(不超过15℃)下保存,给储存和携带增添了不便。中国发明专利申请号202010227177.0中提供了另一种(I)所示化合物的组合物及其制备方法,以该方法制备的药物制剂能在室温(不超过30℃)下稳定储存,但也存在过饱和浓度维持时间短的问题。从该专利文献效果实施例2的表7结果可知,实施例G1~L1各处方样品在360min时间点的溶出仅为最高点的38.9%~76.3%,部分药物在增溶后又发生了过饱和析出。
药物的溶出是口服吸收进入体内发挥疗效的前提条件。药物口服后,通常在口腔和食道内停留小于1min,在胃中停留0.5~2h,在小肠中停留6~8h,在大肠中停留10~20h,在整个消化道停留时间可长达24h,甚至更久。因此,通过制剂技术维持更长时间的稳定过饱和浓度有助于实现增溶和增效的目的。
有鉴于此,开发能够实现式(I)的化合物在溶出过程中更长时间维持过饱和浓度的组合物和/或制剂、及其制备方法十分必要。
发明内容
本发明的目的在于提供一种包含环状膦酸酯化合物的药物组合物,其能够实现所述环状膦酸酯化合物在溶出过程中更长时间维持过饱和浓度,而且由该组合物获得的制剂能够满足制备过程中有关物质未见显著性增加,符合工业化生产的需要,并且其最终制剂产品也适合在室温(小于30℃)下贮存。
本发明的上述目的是通过以下技术方案实现的:
一种药物组合物,按重量份计,其包含:
1份的如式(I)所示的环状膦酸酯化合物:
和
9至45份药学上可接受的载体,其中所述载体包括一种或者多种选自聚乙烯内酰胺、纤维素衍生物、聚丙烯酸树脂、聚多元醇、聚乙烯醇、或聚氧乙烯的聚合物材料。
优选地,所述药学上可接受的载体有的重量份可以选择例如9至45份、10至40份、12至38份、15至35份、18至32份、20至30份、22至28份、22至25份等,也可以选择上述范围内的任意点值的重量份。
在本发明中,所述式(I)的环状膦酸酯化合物与所述载体使所述药物组合物能够在溶出介质中自发形成纳米胶束的形式。上述式(I)的化合物在水中的溶解度极低而在脂溶性中较高,通过长时间摸索发现,将其与选定种类及配比的聚合物组合,形成组合物或制成固体分散体,能够使其在溶出介质中形成稳定的纳米胶束体系。式(I)的化合物由于其水不溶性、高脂溶性的特点而能够稳定分布于胶束纳米粒子的疏水端,从而实现稳定的过饱和浓度的维持。
根据本发明的实施方案,所述环状膦酸酯化合物以不包含溶剂或结晶水的结晶型粉末或者无定形的形式存在;或者所述环状膦酸酯化合物以水合物或者溶剂化物的形式存在。
根据本发明的实施方案,所述环状膦酸酯化合物以部分无定形或完全无定形的形式存在。优选地,按重量计,所述环状膦酸酯化合物的无定形形式占所述环状膦酸酯化合物总重量大于50%、更优选地大于80%、还更优选地大于90%。例如,所述环状膦酸酯化合物的无定形形式可以占所述环状膦酸酯化合物总重量大于50%、55%、60%、65%、70%、75%、80%、85%或90%。
在本发明中,使所述环状膦酸酯化合物的无定形形式占所述环状膦酸酯化合物总重量的比例大于50%、更优选地大于80%、还更优选地大于90%,无定形状态占比越高,越有利于药物从载体中溶出,溶出速度越快。高浓度过饱和溶液的快速形成,有利于过饱和浓度的更好维持。
优选地,所述聚合物材料为聚乙烯内酰胺。
根据本发明的实施方案,所述聚乙烯内酰胺选自聚维酮(PVP)、共聚维酮(PVP/VA)或聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物中的一种或者多种。
优选地,所述聚乙烯内酰胺为聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物
根据本发明的一种具体实施方案,按重量份计,药物组合物包含:
1份如式(I)所示的环状膦酸酯化合物:
和
9至45份药学上可接受的载体,其中所述载体为聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物。
优选地,所述纤维素衍生物选自甲基纤维素、乙基纤维素、羟丙甲纤维素(HPMC)、羟丙基纤维素(HPC)、甲基羟乙基纤维素(MHEC)、醋酸羟丙甲纤维素琥珀酸酯(HPMC-AS)、羟丙甲纤维素邻苯二甲酸酯(HPMCP)或邻苯二甲酸醋酸纤维素(CAP)中的一种或者多种。
优选地,所述聚丙烯酸树脂选自甲基丙烯酸共聚物、甲基丙烯酸酯共聚物、甲基丙烯酸-丙烯酸乙酯共聚物或氨基甲基丙烯酸共聚物中的一种或者多种。
优选地,所述聚多元醇为聚乙二醇。
根据本发明的实施方案,所述药物组合物还包含作为非聚合物材料的药学上可接受的辅料。
优选地,所述药学上可接受的辅料选自弱酸性无机物、中性无机物或熔点低于80℃的药学上可接受的辅料中的一种或多种。
优选地,所述弱酸性无机物为非挥发性弱酸性无机物。
优选地,所述熔点低于80℃的药学上可接受的辅料选自脂质材料、抗氧化剂或表面活性剂中的一种或多种。
优选地,所述脂质材料选自柠檬酸三乙酯、乙酰化柠檬酸三乙酯、丙二醇双葵酸酯、中链甘油三酯、单亚油酸甘油酯、单油酸甘油酯、二乙二醇单乙基醚、氢化蓖麻油、肉豆蔻醇、十六醇、十六十八醇、十八醇、硬脂酸、棕榈酸、棕榈硬脂醇、单油酸甘油酯、聚甘油油酸酯、单硬脂酸甘油酯、双硬脂酸甘油酯、双棕榈酸硬脂酸甘油酯或山嵛酸甘油酯中的一种或多种。
优选地,所述抗氧化剂选自2,6-二叔丁基对甲酚和/或维生素E。
优选地,所述表面活性剂选自泊洛沙姆188、泊洛沙姆407、15-羟基硬脂酸聚乙二醇酯(HS15)、十二烷基硫酸钠、丙二醇单辛酸酯、油酸聚乙二醇甘油酯(LabrafacTM lipophile WL1349)、丙二醇单月桂酸酯、月桂酸聚乙二醇甘油酯(44/14)、硬脂酸聚乙二醇甘油酯(/>50/13)、辛酸葵酸聚乙二醇甘油酯/>失水山梨醇脂肪酸酯聚氧乙烯醚(吐温)、失水山梨醇脂肪酸酯(司盘)、维生素E聚乙二醇琥珀酸酯中的一种或多种。
本发明还提供了本发明所述药物组合物的制备方法,其包括采用所述药物组合物的组分通过热熔融挤出法、喷雾干燥法或溶剂蒸发法制备,优选地通过热熔融挤出法或喷雾干燥法制备,更优选地通过热熔融挤出法制备。
经上述方法制备后,如式(I)所示的环状膦酸酯化合物可以以结晶态存在于组合物中,也可以以无定形态存在于组合物中,还可以一部分以结晶态、一部分以无定形态存在于组合物中。
根据本发明的实施方案,所述制备方法还包括将制备的药物组合物进一步粉碎或者切割成颗粒或粉末。所得颗粒或粉末可以直接灌入胶囊制成胶囊剂,也可以包装成颗粒制成颗粒剂。
根据本发明的实施方案,所述制备方法还包括将所得组合物的颗粒或者粉末与其他药用辅料,如其他药学上可接受的载体、赋形剂和/或稀释剂混合,进一步加工成片剂、胶囊剂、颗粒剂或者干混悬剂等。当本发明的药物组合物用作口服制剂时,所述口服制剂为片剂或胶囊。
本发明还提供了上述药物组合物、或根据上述制备方法获得的药物组合物在制备甲状腺激素β受体激动剂和/或治疗肝病的药物中的用途。本发明的药物组合物可以用于制备降低低密度脂蛋白、甘油三酯水平,减少脂肪毒性并改善肝功能,减少肝脏脂肪的适应症的药物,也可以用于制备治疗非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)适应症的药物。
本发明至少具有如下有益效果:
(1)本发明所提供的药物组合物能够通过形成纳米胶束,延长环状膦酸酯化合物的过饱和浓度维持时间,从而获得更加稳健的溶出。
(2)由本发明所提供的药物组合物获得的制剂能够满足药物制备过程中有关物质未见显著性增加的要求,符合工业化生产的需要,并且制剂产品适合在室温(小于30℃)下贮存。
附图说明
以下,结合附图来详细说明本发明的实施方案,其中:
图1为按照实施例1中的A1~C1组合物处方制得的样品的溶出曲线(n=6);
图2为按照实施例2中的a2组合物处方制得的样品的溶出曲线(n=6)。
具体实施方式
下面结合具体实施方式对本发明进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。
实施例1
在本实施例中,以表1中所列的处方组成制备组合物。
表1.处方组成及处方编号
制备工艺如下:
1.原辅料预处理:以制剂技术的常规手段,对拟用于处方研究的原辅料进行粉碎、过筛、烘干等处理,去除贮存过程中的结块,降低易吸湿辅料的水分,使其符合进一步制备的标准;
2.配料:按上述处方比例及制剂规模,称取热熔融挤出用原辅料;
3.混合:将配料完成的原辅料,以制剂技术常规手段混合均匀;
4.热熔融挤出:针对挤出机的不同区分别进行挤出温度的设置;待预热至设定温度后,保温15min~30min,以手工加料或者失重式自动加料器加料的方式均匀加入混匀的原辅料,以预设的挤出速度挤出;通过调整挤出机筒不同区域的温度、螺杆转速和加料速度,将挤出模头温度控制在90℃~130℃之间,螺杆扭矩保持在稳定的范围内,挤出后物料呈透明状;调整挤出速度和加料速度,使物料在热熔挤出机桶内的滞留时间控制在30min以内;
5.挤出物粉碎:以制剂技术的常规手段,对冷却后的挤出物进行粉碎;
6.总混:按上述处方比例,加入外加的其他辅料,以制剂技术的常规混合手段对上述物料进行混合;
7.制成制剂:将处方A1和C1压制成囊型片;将处方B1的总混物灌入Vcaps Plus型3号羟丙甲纤维素胶囊中;
8.包装:将处方A1和B1的片剂以及处方B1的胶囊装入高密度乙烯瓶中,铝膜封口;
9.保存:将包装完毕的瓶装式(I)所示化合物的片剂或胶囊置于室温(小于30℃)保存。
实施例2
在本实施例中,以表2中所列的处方组成制备组合物。
表2.处方组成及处方编号
制备工艺如下:
1.原辅料预处理:以制剂技术的常规手段,对拟用于处方研究的原辅料进行粉碎、过筛、烘干等处理,去除贮存过程中的结块,降低易吸湿辅料的水分,使其符合进一步制备的标准;
2.配料:按处方比例及制剂规模,称取热熔融挤出用原辅料;
3.混合:将配料完成的原辅料,以制剂技术的常规手段混合均匀;
4.热熔融挤出:针对挤出机的不同区分别进行挤出温度的设置;待预热至设定温度后,保温15min~30min,以手工加料或者失重式自动加料器加料的方式均匀加入混匀的原辅料,以预设的挤出速度挤出;通过调整挤出机筒不同区域的温度、螺杆转速和加料速度,将挤出模头温度控制在100℃~130℃之间,螺杆扭矩保持在稳定的范围内,挤出后物料呈透明状;调整挤出速度和加料速度,使物料在热熔融挤出机桶内的滞留时间控制在30min以内;
5.挤出物粉碎:以制剂技术的常规手段,对冷却后的挤出物进行粉碎;
6.总混:按处方比例,加入外加的其他辅料,以制剂技术的常规混合手段对上述物料进行混合;
7.制成制剂:将处方a2压制成囊型片剂;
8.包装:将处方a2的片剂装入高密度乙烯瓶中,铝膜封口;
9.保存:将包装完毕的瓶装式(I)所示化合物的片剂或胶囊置于室温(小于30℃)保存。
效果实验例1
本实验例以pH递增的溶出24h试验设计阐述本发明组合物比例和制备工艺选择的原因。
取按实施例1的A1~C1处方经热熔融挤出后粉碎得到的颗粒,按实施例2的a2处方经热熔融挤出后粉碎得到的颗粒,各6份进行模拟人体消化液pH转变和过饱和维持时间的考察。
溶出条件为:先以37℃±0.5℃、750mL脱气的pH 2.0盐酸溶液为溶出介质,桨法50rpm搅拌溶出2h,再加入250mL脱气的200mM浓度的pH 6.8磷酸盐缓冲溶液,继续桨法50rpm搅拌溶出22h。其中颗粒以直接精密称取后投入,并分别在投入后的30、60、90、120、180、240、360、480、720、960、1200和1440min取样,取续滤液,加等比例的75%乙腈水溶液稀释,以HPLC法测定式(I)化合物的浓度,计算不同时间点下式(I)化合物的累积溶出百分比。
HPLC测定条件:选择十八烷基硅烷键合硅胶为填充剂(WelchXB-C184.6*150mm,5μm,或与之相当的色谱柱)的色谱柱,以0.05%三氟乙酸水溶液-乙腈(30:70)为流动相,流速1.0mL/min,柱温30℃,检测波长230nm。精密量取对照品溶液和供试品溶液(其中2mg规格处方进样体积为40μL,5mg和10mg规格处方进样提交为20μL),分别注入液相色谱仪,记录色谱图,按外标法以峰面积计算溶出量。
结果如下:
I.如表3和图1所示,以本发明实施例1比例处方制备的挤出物,式(I)化合物均可实现24h内稳健的过饱和溶出,24h终点的溶出相对测得的最高点的溶出度为88.8%~100.0%。
II.如表4和图2所示,实施例2中式(I)化合物在溶出过程中发生了较明显的过饱和析出现象,24h终点的溶出相对测得的最高点的溶出度较低,为28.3%。
III.溶出曲线下面积计算,实施例1分别为实施例2的171.2%(83104.5/48549.0*100%)、170.2%(82648.5/48549.0*100%)和211.0%(102456.0/48549.0*100%)。
结论如下:实施例1和实施例2的溶出对比结果表明,采用实施例1所述的技术方案,在维持式(I)化合物的长时间的稳健的过饱和浓度方面具有更加特别的优势。
表3.实施例1中的不同处方样品的溶出结果(n=6)
表4.实施例2中的不同处方样品的溶出结果(n=6)
效果实验例2
由于900mL溶出杯内(I)化合物和载体辅料制成的胶束体系浓度过稀,难以用激光粒度法测定。以如下改进的方法,对实施例1和实施例2可能形成的胶束粒径进行比较。
分别取由实施例1和实施例2所获得的含有5mg式(I)化合物的组合物挤出物粉末,添加至100mL量瓶中,添加37.0℃±0.5℃的50mM浓度的pH 6.0磷酸缓冲液定容,并在37.0℃±0.5℃水浴中振摇15min,使之充分溶解分散。用NICOMPTM 380ZLS型激光粒度仪进行对样品进行测定。以高斯分布(Gaussian Distribution)的光强(Intensity)计算胶束的粒径分布,结果如表5所示。
表5.粒径测定结果
粒径测定结果表明,实施例1中制备得到的纳米胶束相对于实施例2方案制备的胶束,粒径更小,分布更集中,提示具有更好的稳定性。
以上所述,仅是本发明的几个示例性实施例,并非对本发明做任何形式的限制。虽然本发明以较佳的实施例揭示如上,然而并非用以限制本发明。任何熟悉本专业的技术人员,在不脱离本发明技术方案的范围内,利用上述揭示的技术内容做出些许的变动或修饰均等同于等效实施案例,均属于本发明技术方案范围内。
Claims (10)
1.一种药物组合物,按重量份计,其包含:
1份如式(I)所示的环状膦酸酯化合物:
和
9至45份药学上可接受的载体,其中所述载体包括一种或者多种选自聚乙烯内酰胺、纤维素衍生物、聚丙烯酸树脂、聚多元醇、聚乙烯醇或聚氧乙烯的聚合物材料。
2.根据权利要求1所述的药物组合物,其中,所述环状膦酸酯化合物以不包含溶剂或结晶水的结晶型粉末或者无定形的形式存在;或者所述环状膦酸酯化合物以水合物或者溶剂化物的形式存在。
3.根据权利要求1或2所述的药物组合物,其中,所述环状膦酸酯化合物以部分无定形或完全无定形的形式存在;
优选地,按重量计,所述环状膦酸酯化合物的无定形形式占所述环状膦酸酯化合物总重量大于50%、更优选地大于80%、还更优选地大于90%。
4.根据权利要求1所述的药物组合物,其中,所述聚合物材料为聚乙烯内酰胺;所述聚乙烯内酰胺选自聚维酮、共聚维酮或聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物中的一种或者多种;
优选地,所述聚乙烯内酰胺为聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物。
5.根据权利要求4所述的药物组合物,按重量份计,其包含:
1份如式(I)所示的环状膦酸酯化合物;和
9至45份药学上可接受的载体,其中所述载体为聚乙烯己内酰胺-聚乙酸乙烯酯-聚乙二醇接枝共聚物。
6.根据权利要求1所述的药物组合物,其中,所述纤维素衍生物选自甲基纤维素、乙基纤维素、羟丙甲纤维素、羟丙基纤维素、甲基羟乙基纤维素、醋酸羟丙甲纤维素琥珀酸酯、羟丙甲纤维素邻苯二甲酸酯或邻苯二甲酸醋酸纤维素中的一种或者多种。
7.根据权利要求1所述的药物组合物,其中,所述聚丙烯酸树脂选自甲基丙烯酸共聚物、甲基丙烯酸酯共聚物、甲基丙烯酸-丙烯酸乙酯共聚物或氨基甲基丙烯酸共聚物中的一种或者多种;
优选地,所述聚多元醇为聚乙二醇。
8.根据权利要求1至7中任一项所述的药物组合物,其中,所述药物组合物还包含作为非聚合物材料的药学上可接受的辅料;
优选地,所述药学上可接受的辅料选自弱酸性无机物、中性无机物或熔点低于80℃的药学上可接受的辅料中的一种或多种;
优选地,所述弱酸性无机物为非挥发性弱酸性无机物;
优选地,所述熔点低于80℃的药学上可接受的辅料选自脂质材料、抗氧化剂或表面活性剂中的一种或多种。
9.制备权利要求1至8中任一项所述的药物组合物的方法,其包括采用权利要求1至8中任一项所述的药物组合物的组分通过热熔融挤出法、喷雾干燥法或溶剂蒸发法制备,优选地通过热熔融挤出法或喷雾干燥法制备,更优选地通过热熔融挤出法制备;
优选地,所述方法还包括将制备的药物组合物进一步粉碎或切割成颗粒或粉末。
10.权利要求1至8中任一项所述的药物组合物、或根据权利要求9所述的方法制备获得的药物组合物在制备甲状腺激素β受体激动剂和/或治疗肝病的药物中的用途。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210172544.0A CN116687850A (zh) | 2022-02-24 | 2022-02-24 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
PCT/US2022/071221 WO2023163795A1 (en) | 2022-02-24 | 2022-03-18 | Cyclic phosphonate composition and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210172544.0A CN116687850A (zh) | 2022-02-24 | 2022-02-24 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116687850A true CN116687850A (zh) | 2023-09-05 |
Family
ID=81392887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210172544.0A Pending CN116687850A (zh) | 2022-02-24 | 2022-02-24 | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116687850A (zh) |
WO (1) | WO2023163795A1 (zh) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL142650A (en) | 1998-04-08 | 2007-06-03 | Galmed Int Ltd | Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes |
IL123998A (en) | 1998-04-08 | 2004-09-27 | Galmed Int Ltd | Conjugates of bile salts and pharmaceutical preparations containing them |
RS50045B (sr) | 1999-03-29 | 2008-11-28 | F.Hoffmann-La Roche Ag., | Aktivatori glukokinaze |
US8975246B2 (en) | 2001-04-17 | 2015-03-10 | Galmed Research And Development Ltd. | Bile acid or bile salt fatty acid conjugates |
EP2408774B1 (en) | 2009-03-20 | 2014-11-26 | Metabasis Therapeutics, Inc. | Inhibitors of diacylglycerol o-acyltransferase 1(dgat-1) and uses thereof |
CN113274368B (zh) * | 2020-02-20 | 2023-08-22 | 甘莱制药有限公司 | 一种用于治疗脂肪性肝炎的药物组合物及其制备方法 |
CN115427022B (zh) * | 2020-03-27 | 2024-02-20 | 甘莱制药有限公司 | 药物组合物、制备方法及其使用方法 |
-
2022
- 2022-02-24 CN CN202210172544.0A patent/CN116687850A/zh active Pending
- 2022-03-18 WO PCT/US2022/071221 patent/WO2023163795A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2023163795A1 (en) | 2023-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roblegg et al. | Development of sustained-release lipophilic calcium stearate pellets via hot melt extrusion | |
AU2009236289B2 (en) | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and HPMCAS | |
EP2200588B1 (en) | Compositions comprising lipophilic active compounds and method for their preparation | |
US6511681B2 (en) | Aqueous solubility pharmaceutical formulations | |
CN101835492B (zh) | 用于制药应用的热动力学混合 | |
CZ292146B6 (cs) | Protiplísňový orální prostředek obsahující itrakonazol a způsob jeho přípravy | |
KR20070119700A (ko) | 페노피브레이트 및 계면 활성제 혼합물을 함유하는 제제 | |
KR20070113289A (ko) | 멘톨 또는 peg/폴록사머를 함유하는 개선된페노피브레이트 제제 | |
US20230364114A1 (en) | Pharmaceutical compositions, method of making and method of using thereof | |
US5684040A (en) | Compositions in the form of solid solutions | |
US7666860B2 (en) | Melt-formulated, multi-particulate oral dosage form | |
CN116687850A (zh) | 包含环状膦酸酯化合物的药物组合物及其制备方法与用途 | |
CN113350290A (zh) | 一种阿瑞匹坦固体分散组合物及其制备方法 | |
Pandey et al. | Enhancement of dissolution rate and bioavailability of Paliperidone by Hot Melt Extrusion technique | |
CN105050586B (zh) | 包含非晶西洛他唑的固体分散体 | |
TW201609108A (zh) | 醫藥劑型 | |
WO2013030119A1 (de) | Darreichungsform mit stabilisierten wirkstoffpartikeln | |
US11752161B2 (en) | Pharmaceutical compositions, method of making and method of using thereof | |
CN114555061B (zh) | 一种奥利司他胶囊及其制备方法 | |
CN115531329A (zh) | 一种稳定的艾地骨化醇片 | |
CN115554246A (zh) | 一种肠道定位释放的布地奈德固体分散体及其制备方法 | |
CA3236956A1 (en) | Solid dispersion, preparation method therefor, and solid formulation comprising same | |
CN114681433A (zh) | 一种醋酸阿比特龙口腔速溶膜剂及其制备方法 | |
AU2014265059A1 (en) | Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas | |
WO2011000126A1 (zh) | 脂溶性药物组合物、制备方法及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40090396 Country of ref document: HK |